ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

EKF Ekf Diagnostics Holdings Plc

32.55
-0.45 (-1.36%)
20 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Ekf Diagnostics Holdings Plc LSE:EKF London Ordinary Share GB0031509804 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.45 -1.36% 32.55 32.20 32.90 - 151,755 16:35:04
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Med, Dental, Hosp Eq-whsl 52.61M 2.35M 0.0052 63.46 150.13M
Ekf Diagnostics Holdings Plc is listed in the Med, Dental, Hosp Eq-whsl sector of the London Stock Exchange with ticker EKF. The last closing price for Ekf Diagnostics was 33p. Over the last year, Ekf Diagnostics shares have traded in a share price range of 22.50p to 37.50p.

Ekf Diagnostics currently has 454,930,564 shares in issue. The market capitalisation of Ekf Diagnostics is £150.13 million. Ekf Diagnostics has a price to earnings ratio (PE ratio) of 63.46.

Ekf Diagnostics Share Discussion Threads

Showing 4426 to 4449 of 4875 messages
Chat Pages: Latest  183  182  181  180  179  178  177  176  175  174  173  172  Older
DateSubjectAuthorDiscuss
03/7/2022
12:45
Love technical acronyms. As Peter Lynch used to say, there is a strong negative correlation between numbers of acronyms one employs (under the guise of "research") and the quality of their calls. This board is testament to that ain't it.
tongosti
01/7/2022
16:30
And of course it means that Quo-Test can be deployed in EKF/ADL US Labs
wan
01/7/2022
16:28
In the US EKF's Quo-Test is FDA 510K cleared for professional use in a clinical laboratory setting, so it will be very interesting to see if EKF's Link provides the catalyst for US sales of this analyser (and indeed increases sales across the EKF portfolio a whole).
wan
01/7/2022
15:43
70% down man - at some point we will get the inevitable bounce. Doesn't require much thinking that does it. You too have a good weekend old chap.
tongosti
01/7/2022
14:23
'On plan' news -

Industry News: EKF to highlight specific glycemic control marker at AACC 2022
EKF Diagnostics exhibiting range of tests and analyzers on Booth #3637
30 Jun 2022

EKF Diagnostics, a global in vitro diagnostics company, will be at the 2022 AACC Clinical Lab Expo, Chicago IL, July 26-28, exhibiting its range of laboratory and point-of-care diagnostics products on Booth #3637. This includes the FDA cleared Lucica® Glycated Albumin-L test kit, manufactured by Asahi Kasei Pharma Corporation and sold exclusively in the U.S. by EKF. A specific, quantitative test for glycated albumin, it is one of the most widely published methods worldwide used for the intermediate term monitoring of glycemic control in diabetes patients.

Lucica® Glycated Albumin-L is an enzymatic methodology for use on compatible clinical chemistry analyzers with open channel capability, making it accurate and cost-effective to perform. It determines both glycated albumin and total albumin in separate reactions and the results are expressed as a ratio (%), minimizing differences in albumin concentrations between patients. Lucica® is also standardized to an established reference material.

“The Lucica® Glycated Albumin-L is sold exclusively by EKF Diagnostics in the U.S. and complements our existing diabetes product range, offering its own utility as a specific, intermediate glycemic control marker,” said Shane O’Neill, Global Director of Scientific Affairs, EKF Diagnostics.

Alongside its range of clinical chemistry tests and diagnostics analyzers, also available to view on EKF’s Booth at AACC will be its newly launched EKF Link digital connectivity solution. The downloadable software package offers secure management of point-of-care (POC) analyzers and associated data on one centralized platform. This delivers essential digital connectivity with traceability that is increasingly required for safe, secure, and effective POC testing using analyzers in many differing locations.

EKF Link middleware is an open and flexible solution which can be interfaced to all vendors’ POC analyzers, including EKF’s own portfolio, to enable real-time remote management of data, including patient test results, QC results, operator management, and analyzer configuration. The user-friendly software allows POC analyzers to connect to a hospital or laboratory’s IT system, enabling data transfer from the remote analyzers for subsequent processing. This provides hospitals, laboratories, and clinicians with the functionality to manage and evaluate their patient and operator data easily and securely.

EKF’s portfolio of POC diagnostic devices includes Hemo Control and DiaSpect Tm hemoglobin analyzer ranges, as well as Quo-Lab and Quo-Test HbA1c analyzers. All of these can now be digitally connected from anywhere and securely accessed remotely at any time using EKF Link, thereby enhancing their capabilities.


Recall from the EKF Link RNS -

The development and launch of EKF Link has been driven by customer demand and designed in partnership with hospital POC managers to ensure the software meets their specific needs. EKF Link provides the Company with improved competitive positioning for future POC contract tenders and new accounts, and increases the attractiveness of the EKF product portfolio to existing customers against currently available technologies.

Mike Salter, CEO, of EKF Diagnostics said: "As part of our strategy to enhance our POC analyser portfolio and technology offering, we are pleased to announce that we have successfully launched EKF Link enabling practitioners to analyse their patients' results remotely, easily and securely. EKF Link provides our POC diagnostic devices with a connectivity advantage which positions us well for tenders and new accounts. This is particularly true in Europe and North America, where a connectivity solution is commonly a part of the specification. EKF Link has the added benefit that it can be installed wherever it is needed, on a PC or a central server, allowing hospitals and laboratories, technicians and clinicians to access results from various settings, reducing workload whilst increasing the security of handling patient data.

"This new product launch shows our responsiveness to our customer base and increasing demand for data management capabilities. It extends the utility of our installed instrument base and provides EKF with a key advantage for further new business opportunities."

wan
29/6/2022
20:18
Wan - any idea why octopus fund did what they did as per latest RNS? Ta.
tongosti
28/6/2022
20:10
Mediocrity requires company. Here's a good evening to the 80+ crowd!
tongosti
28/6/2022
15:39
Sooty Snipes - Please just filter like the rest of us. It stops the board being clogged up with drivel.
james188
28/6/2022
15:17
Some take city managers' words as gospel. Was simply making the point that beta parades as alpha more often than not. Very relevant in this game (if you know what you're doing of course). Ta.
tongosti
28/6/2022
15:01
Jeez I'm a newcomer here at 32p but give it a rest mate. You talk more than my misses. You should change your name to Yap Yap
sooty snipes
28/6/2022
14:51
Research idea:

one goes back 3 / 5 / 10 years and compares his performance relative to SPX with the view to establish who who has bested who. passive has beaten active hands down. ah - passive is much cheaper too.

tongosti
28/6/2022
14:09
The fella who was equally bullish at 80+ you mean? Lol

PS. To borrow from WB - when was the last time the barber said you don’t need a haircut?

tongosti
28/6/2022
14:07
Christopher Mills of Harwood Capital talks about EKF here (starts 23:15)

www.linkedin.com/posts/paul-hill-a5994116_vox-markets-fund-manager-interview-with-christopher-activity-6947490289783603200-5DnF?utm_source=linkedin_share&utm_medium=member_desktop_web

hxxps://www.voxmarkets.co.uk/articles/vox-markets-fund-manager-interview-with-christopher-mills-3caf5ae

brummy_git
28/6/2022
08:52
Investors at what price pal - those at 80+ (who are down huge) or those at 30? Entry price matters darling (doesn't matter what time horizon you’re a fan of).

P.S. For all the nonsense one hears around that price doesn't matter to "long termers", actually it does. Pythagora's proof - when one is long P&L = P2-P1 Translation - the lower P1 the higher the profit. irrefutable proof that price MATTERS - big time.

tongosti
28/6/2022
07:57
Notable volumes of late.

What I can also see is EKF purposefully and unwaveringly getting on with expanding their core business, as well as implementing various aspects of their Growth Strategy 2024.

That might be boring for some, but I maintain my view that EKF investors are likely to be rewarded for their patience.

wan
27/6/2022
19:09
Bliss:

tongosti 23 Jun '22 - 08:48 - 2824 of 2829 (Filtered)

buywell3 23 Jun '22 - 09:14 - 2825 of 2829 (Filtered)

tongosti 23 Jun '22 - 09:25 - 2826 of 2829 (Filtered)

buywell3 23 Jun '22 - 23:54 - 2827 of 2829 (Filtered)

tongosti 24 Jun '22 - 11:42 - 2828 of 2829 (Filtered)

tongosti 27 Jun '22 - 16:34 - 2829 of 2829 (Filtered)

sharw
27/6/2022
16:34
Significant volumes coming in today. Could be interesting. PS. Do we think our resident trillionaire is on a spending spree?
tongosti
24/6/2022
11:42
The day the c-19 vaccine news hit the wires (Nov 2020), this share had a massive collapse. Mr Market was telling us all the previous bull market in ekf had come to an end due to a fundamental shift. You cannot believe the hostility I got here for paying heed to the market's bells. Market leads fundamentals follow - is a truism that has held in the markets. Across geographies and across markets and across time.
tongosti
23/6/2022
09:25
Like your approach too pal. Not to dissimilar to "... in times of universal deceit (best translated as euphoria in the context of financial markets) telling the truth becomes a revolutionary act". I was laughed at 80+ calling the top then. You're right - only by challenging conventional wisdom one sets the truth free.
tongosti
23/6/2022
09:14
You are ruffling some feathers tongosti

But buywell likes your style

-------------------------------------

Negative views need to be aired for the truth to be arrived at by logic and deduction

writ by buywell AD 2022

buywell3
23/6/2022
08:48
What's the trillionaires' club view this morning - following markets on deck of a boat off the coast of Antigua? Lol
tongosti
22/6/2022
17:52
Not on Forbes then?
tongosti
22/6/2022
17:32
Scarlet Pimpernel.

If you can think laterally, and have been around long enough, you will work out what the tag p1nkfish means and who I am. Going for a swim in the evening sunshine before dinner.

Over & out.

p1nkfish
22/6/2022
16:54
I read what you write - that’s the only thing I comment on. Usually you know where folks stand (on the topic being discussed) by what they write.

It's not who (you think) you are - it's the arguments you put forward fella.

Not sure why you're hinting at whatever success you think you have had (whatever it maybe, am happy for you fella) - sounds more like you've run out of arguments.

P.S. In case I have missed you on Forbes - pls remind me with a fresh link. Ta

tongosti
Chat Pages: Latest  183  182  181  180  179  178  177  176  175  174  173  172  Older

Your Recent History

Delayed Upgrade Clock